B·R·A·H·M·S GmbH explores, develops, and produces new diagnostic test procedures to improve the diagnosis and thereby the treatment of life-threatening illnesses worldwide. It offers thermo scientific biomarkers. The company’s biomarkers focus on research into biomarkers for in vitro diagnosis in medically relevant indications, such as sepsis; markers for intensive care and cardiovascular diseases; lung diseases; prenatal screening/down's syndrome; tumour diseases; and technology transferor and new technologies. Its products are used for tumor diseases, fertility, prenatal screening, and diseases of the thyroid. The company was founded in 1994 and is based in Hennigsdorf, Germany. B·R·A·H·M·...
Founded in 1994
diaDexus, Inc. Enters into a License and Supply Agreement with B.R.A.H.M.S. Gmbh
Mar 5 14
On March 4, 2014, diaDexus Inc. entered into a License and supply agreement with B.R.A.H.M.S. GmbH, which is part of Thermo Fisher Scientific Inc. family of companies. Under the agreement, the company obtained an exclusive license from BRAHMS to develop and commercialize high throughput immunoassays for three independent biomarkers (MR-proADM and MR-proANP and CT-proET-1) in the United States for the prognosis or diagnosis of cardiac or cardiovascular disease. The agreement also provides the company with an option to obtain a co-exclusive license in additional countries outside the United States, subject to reasonable payments to be negotiated. The company will be responsible for the development of the licensed immunoassay products, using the biological materials purchased from BRAHMS. Upon completion of the development of the licensed immunoassay products, the company will transfer the commercial production of any such licensed immunoassay products to BRAHMS and company will purchase the licensed immunoassay products from BRAHMS for commercial sale at a specified cost-based transfer price. The agreement includes customary terms, such as forecast, ordering, delivery, inspection for the purchase and supply of licensed immunoassay products. The agreement will expire upon the expiration of the licensed patents covering the licensed immunoassay products, and may be terminated by either party for the other party’s uncured material breach upon written notice. In addition, the company may terminate the agreement upon a minimum specified days advance written notice to BRAHMS, and BRAHMS may terminate the agreement immediately if the company challenges any licensed patents.